These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33771759)

  • 1. Inflammation-targeted therapies and cancer.
    Kedra J; Nocturne G; Mariette X; Seror R
    Joint Bone Spine; 2021 Jul; 88(4):105176. PubMed ID: 33771759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence.
    Singh N; Li CI
    Curr Opin Rheumatol; 2021 May; 33(3):292-299. PubMed ID: 33741804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
    Maneiro JR; Souto A; Gomez-Reino JJ
    Semin Arthritis Rheum; 2017 Oct; 47(2):149-156. PubMed ID: 28284845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 7. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy.
    Xie W; Xiao S; Huang Y; Sun X; Gao D; Ji L; Li G; Zhang Z
    Rheumatology (Oxford); 2020 May; 59(5):930-939. PubMed ID: 31620795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
    Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register.
    Molina-Collada J; Alonso F; Otero L; Bohórquez C; Díaz Torné C; Pérez García C; Blanco Madrigal JM; Vela P; Álvaro-Gracia JM; Castrejón I;
    Semin Arthritis Rheum; 2024 Feb; 64():152341. PubMed ID: 38128174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics, cardiovascular effects and cancer.
    Damjanov N; Nurmohamed MT; Szekanecz Z
    BMC Med; 2014 Mar; 12():48. PubMed ID: 24642038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewé RBM
    Ann Rheum Dis; 2017 Jun; 76(6):1101-1136. PubMed ID: 28298374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
    Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignancy and the Risks of Biologic Therapies: Current Status.
    Seror R; Mariette X
    Rheum Dis Clin North Am; 2017 Feb; 43(1):43-64. PubMed ID: 27890173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Singh S; Fumery M; Singh AG; Singh N; Prokop LJ; Dulai PS; Sandborn WJ; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):561-576. PubMed ID: 30875456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
    Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
    Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
    Singh JA
    Curr Rheumatol Rep; 2016 Oct; 18(10):61. PubMed ID: 27613285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
    Park HJ; Ranganathan P
    Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers.
    de La Forest Divonne M; Gottenberg JE; Salliot C
    Joint Bone Spine; 2017 Mar; 84(2):133-140. PubMed ID: 27341745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.